Rethinking lymphodepleting preconditioning in adoptive T cell therapy for durable tumor control

Molecular Therapy: Oncology · Published 2026-08-01 · DOI 10.1016/j.omton.2026.201293

Free full text

Authors (3)

Diego Figueroa, Vincenzo Borgna, Alvaro Lladser

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2026

Citation

Figueroa, D., Borgna, V., Lladser, A. (2026). Rethinking lymphodepleting preconditioning in adoptive T cell therapy for durable tumor control. Molecular Therapy: Oncology. https://doi.org/10.1016/j.omton.2026.201293

Related articles

• Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy · Molecular Therapy: Oncology · 2026 · Same journal
• AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer · Molecular Therapy: Oncology · 2026 · Same journal
• CART-immune-related adverse events after BCMA CAR-T therapy · Molecular Therapy: Oncology · 2026 · Same journal
• Unmasking Wnt-driven HCC: Inhibiting SMYD2 to overcome immune resistance · Molecular Therapy: Oncology · 2026 · Same journal
• Intraperitoneal delivery of the oncolytic virus CF17 improves tumor immunogenicity and survival in gastric cancer peritoneal metastasis · Molecular Therapy: Oncology · 2026 · Same journal
• Synergistic Cell-Cycle Repression by HDAC/EZH2 Co-Targeting in H3K27-Altered Diffuse Midline Glioma · Molecular Therapy: Oncology · 2026 · Same journal
• Natural killer cell-derived extracellular vesicles reprogram cellular human immunity to enhance tumor cytotoxicity · Molecular Therapy: Oncology · 2026 · Same journal
• CAR design equips diverse immune cells with unique antigen-specific activation identities · Molecular Therapy: Oncology · 2026 · Same journal
• Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations · Molecular Therapy: Oncology · 2026 · Same journal
• Strategies to prevent HNSCC by chewing gum delivery of enzymes/antimicrobials to reduce carcinogenic acetaldehyde produced by pathogenic microbes · Molecular Therapy: Oncology · 2026 · Same journal